$AMTI News

Last published 2y ago

2y agoAMTI CYTHCyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.Business WireCombined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with
2y agoAMTI CYTH RFLCyclo Therapeutics Reports Third Quarter 2023 Financial ResultsBusiness WireStrong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") Merger with Applied Molecular Transport,
3y agoAMTIApplied Molecular Transport Reports Third Quarter 2023 Financial ResultsGlobeNewswireCompany Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied
3y agoAMTI CHS ICPT SPLKMoore Kuehn Encourages AMTI, SPLK, ICPT, and CHS Investors to Contact Law FirmPR NewswireNEW YORK, Oct. 4, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
3y agoAMTI CYTHCyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger AgreementBusiness WireCombined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have
3y agoAMTIApplied Molecular Transport Reports Second Quarter 2023 Financial ResultsGlobeNewswireCurrently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE
3y agoAMTIApplied Molecular Transport Reports First Quarter 2023 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a biopharmaceutical company, today reported financial results for the first quarter ended March 31,
3y agoAMTIApplied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic AlternativesGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company's board of directors
3y agoAMTIApplied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswireExploring strategic partnership options to advance AMT-101 for chronic pouchitis, an orphan indication with no FDA-approved products Evaluating next steps for the company's second clinical asset, AMT-126 SOUTH SAN
3y agoAMTIApplied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO '23 CongressGlobeNewswireNew positive data demonstrate oral AMT-101's gut-restricted profile with tissue-level pharmacodynamics (PD) effects and no systemic exposure by design Translational analysis reveals IL-10 biological responses in both
3y agoAMTIApplied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative ColitisGlobeNewswire– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 – AMT-101 was well-tolerated – Planned Phase 1b trial for the company's second clinical asset,
4y agoAMTIApplied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of PouchitisGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for
4y agoAMTIApplied Molecular Transport to Present at Upcoming November Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation at the following
4y agoAMTIApplied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireCompany held end of Phase 2 meeting with FDA to discuss advancing oral AMT-101 monotherapy to Phase 3 in chronic pouchitis, an orphan indication with no FDA-approved products Anticipate Phase 2 top-line readout for oral
4y agoAMTIApplied Molecular Transport Completes Enrollment of Phase 2 LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative ColitisGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the company has completed enrollment of the Phase 2 LOMBARD trial for AMT-
4y agoAMTIApplied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireAnnounced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Orphan indication with no FDA-approved products Company granted end of Phase 2 meeting with FDA to discuss advancing into Phase 3 development Announced top-
4y agoAMTISAD Study to Assess the Safety, Tolerability, PK, and In-Vivo Performance of AMT-126 in Healthy Male and Female Subjects - NCT05476107ClinicalTrials.govIncidence of Treatment-emergent adverse events (safety and tolerability), To assess the in vivo performance of an AMT-126 tablet formulation (Optional, Part 2 only), To assess pharmacokinetics of AMT-126 in healthy volunteers
4y agoAMTIApplied Molecular Transport Announces Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative ColitisGlobeNewswire– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8 – Post hoc analysis of patients with shorter duratio
4y agoAMTIApplied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative ColitisGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selecti
4y agoAMTIApplied Molecular Transport to Present at Upcoming June Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation in fireside chats at the following investor conferences:
4y agoAMTIApplied Molecular Transport Provides Strategy UpdateGlobeNewswireCompany streamlines to prioritize resources on key proprietary clinical programs, including plans to advance AMT-101 into Phase 3 for chronic pouchitis Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arth
4y agoAMTIStudy of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET) - NCT05372939ClinicalTrials.govUlcerative Colitis disease activity as assessed by mean change in UC-100 Score from baseline, Mean change in Robarts Histopathology Index (RHI) from baseline, Mean change in total Mayo Clinic Score (MCS) and component scores (Mayo Endoscopic Subscore [MES], partial MCS, rectal bleeding and stool frequency) from baseline, (and 5 more...)
4y agoAMTIApplied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireAnnounced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and r
4y agoAMTIApplied Molecular Transport to Present at BofA Securities 2022 Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will part
4y agoAMTIApplied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic PouchitisGlobeNewswire– Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)– AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profil
4y agoAMTIApplied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic PouchitisGlobeNewswire- Live Conference Call and Webcast on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., April 24, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the company plan
4y agoAMTIApplied Molecular Transport Announces Publication in Tissue Barriers Providing Additional Insight into Company's Proprietary Technology PlatformGlobeNewswirePublication describes critical interactions between cholix-based transport domain and endogenous intracellular trafficking pathways used by Company's proprietary biologic product candidates to cross intestinal epithelial barrier Deep characterization
4y agoAMTIApplied Molecular Transport Appoints Charlene Banard to its Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Charlene Banard to its Board of Directors. Ms. Banard i
4y agoAMTIApplied Molecular Transport Appoints Industry Veteran Carolyn Finkle as Senior Vice President, Head of Regulatory AffairsGlobeNewswireCompany continues to strengthen key functions and corporate leadership Company on track to announce top-line data from four ongoing oral AMT-101 Phase 2 trials in 2022 SOUTH SAN FRANCISCO, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Applied Molecu
4y agoAMTIApplied Molecular Transport Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswireFour top-line data readouts expected in 2022 from ongoing oral AMT-101 Phase 2 trials, as follows FILLMORE monotherapy trial for patients with chronic pouchitis followed by MARKET combination trial with anti-TNFα in ulcerative colitis (UC) in H1 202
4y agoAMTIApplied Molecular Transport to Present at SVB Leerink Virtual 11th Annual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will par
4y agoAMTIApplied Molecular Transport Announces Board AppointmentsGlobeNewswireJohn W. Smither Appointed to its Board of Directors and Named Audit Committee Chair Graham K. Cooper Named Executive Chair Helen S. Kim Named Lead Independent Director SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Applied Mol
4y agoAMTIApplied Molecular Transport to Present at Virtual Jefferies London Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Bittoo Kanwar, M.D., chief medical officer, and Liz Bhatt, chief busin
5y agoAMTIApplied Molecular Transport Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireTop-line data readout for oral AMT-101 Phase 2 MARKET combination trial with anti-TNFα in ulcerative colitis (UC) expected in H1 2022 Top-line data readouts from three additional oral AMT-101 Phase 2 trials, consistent with previous guidance FILL
5y agoAMTIApplied Molecular Transport to Host Virtual Research & Development Day on October 15, 2021GlobeNewswireManagement to highlight novel oral biologics technology platform, clinical programs and research activities Feature distinguished IBD and rheumatology key opinion leaders Provide update on the four on-going Phase 2 clinical trials for oral AMT-101
5y agoAMTIApplied Molecular Transport Announces Upcoming Investor Events in September and OctoberGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the following investor events in Sept
5y agoAMTIApplied Molecular Transport Appoints Holly Schachner, M.D. to its Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Holly Schachner, M.D. a seasoned and accomplished indust
5y agoAMTIApplied Molecular Transport to Present at Canaccord Genuity's 41st Annual Growth ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will par
5y agoAMTIApplied Molecular Transport Presents Additional Positive Data from Oral AMT-101 Phase 1b in Ulcerative Colitis at ECCO '21 Virtual CongressGlobeNewswireOnce daily, oral AMT-101 was safe and well tolerated, and demonstrated trends of improvement in objective measures of inflammation: fecal calprotectin, CRP, and histology Key findings support oral AMT-101 actively exerts immunomodulatory effect result
5y agoAMTIApplied Molecular Transport to Present at JMP Securities Life Sciences ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will par
5y agoAMTIApplied Molecular Transport to Present at Jefferies Virtual Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will part
5y agoAMTIApplied Molecular Transport to Present at BofA Securities 2021 Health Care ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will part
5y agoAMTIApplied Molecular Transport Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the closing of its...
5y agoAMTIApplied Molecular Transport Announces Pricing of Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the pricing of an...
5y agoAMTIApplied Molecular Transport Announces Proposed Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has...
5y agoAMTIApplied Molecular Transport Appoints Earl Douglas as General CounselGlobeNewswireCompany continues to strengthen key functions of corporate leadership Company on track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials from its comprehensive clinical...
5y agoAMTIApplied Molecular Transport Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateGlobeNewswireSuccessfully initiated four planned Phase 2 trials for oral AMT-101 with enrollment ongoing Company on track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials from its...
5y agoAMTIApplied Molecular Transport to Present at Oppenheimer 31st Annual Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood,...
5y agoAMTIApplied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT-126GlobeNewswireCompany expands pipeline with second clinical program, AMT-126, an oral IL-22 fusion biologic therapy for diseases associated with intestinal epithelial barrier defects IL-22 deficiency implicated in...
5y agoAMTIApplied Molecular Transport to Present at SVB Leerink 10th Annual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood,...